BR112015001096A2 - derivados de di e tri-heteroaril como inibidores de agregação de proteína - Google Patents
derivados de di e tri-heteroaril como inibidores de agregação de proteínaInfo
- Publication number
- BR112015001096A2 BR112015001096A2 BR112015001096A BR112015001096A BR112015001096A2 BR 112015001096 A2 BR112015001096 A2 BR 112015001096A2 BR 112015001096 A BR112015001096 A BR 112015001096A BR 112015001096 A BR112015001096 A BR 112015001096A BR 112015001096 A2 BR112015001096 A2 BR 112015001096A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein aggregation
- triheteroaryl
- derivatives
- aggregation inhibitors
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672239P | 2012-07-16 | 2012-07-16 | |
| PCT/US2013/050719 WO2014014937A1 (en) | 2012-07-16 | 2013-07-16 | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015001096A2 true BR112015001096A2 (pt) | 2017-06-27 |
Family
ID=49949212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015001096A BR112015001096A2 (pt) | 2012-07-16 | 2013-07-16 | derivados de di e tri-heteroaril como inibidores de agregação de proteína |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9284309B2 (https=) |
| EP (1) | EP2872143B1 (https=) |
| JP (1) | JP2015522617A (https=) |
| KR (1) | KR20150031481A (https=) |
| CN (1) | CN104703604A (https=) |
| AU (1) | AU2013290361A1 (https=) |
| BR (1) | BR112015001096A2 (https=) |
| CA (1) | CA2877983A1 (https=) |
| ES (1) | ES2661394T3 (https=) |
| HK (1) | HK1210598A1 (https=) |
| IL (1) | IL236712A0 (https=) |
| IN (1) | IN2015DN01171A (https=) |
| MX (1) | MX2015000618A (https=) |
| RU (1) | RU2015104962A (https=) |
| WO (1) | WO2014014937A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2016009347A0 (en) * | 2014-01-29 | 2016-07-31 | Neuropore Therapies Inc | Heteroarly amides as inhibitors of protein aggregation |
| EP3328379B1 (en) * | 2015-07-29 | 2021-07-28 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| EA201991755A1 (ru) | 2017-01-26 | 2020-01-22 | Юсб Байофарма Спрл | Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков |
| CN110198938B (zh) | 2017-01-26 | 2023-03-14 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的双-杂芳基衍生物 |
| KR20190112031A (ko) * | 2017-01-26 | 2019-10-02 | 유씨비 바이오파마 에스피알엘 | 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체 |
| WO2018158160A1 (en) | 2017-02-28 | 2018-09-07 | Universitat Autonoma De Barcelona | (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies |
| WO2019025424A1 (en) | 2017-08-04 | 2019-02-07 | Universitat Autonoma De Barcelona | COMPOUNDS FOR TREATING SYNUCLEINOPATHIES |
| WO2019161917A1 (en) | 2018-02-23 | 2019-08-29 | Universitat Autonoma De Barcelona | 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies |
| CN113683598B (zh) * | 2020-05-18 | 2022-10-14 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2025223458A1 (zh) * | 2024-04-23 | 2025-10-30 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4739632B2 (ja) | 2000-02-05 | 2011-08-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| EP1317453B1 (en) | 2000-09-15 | 2006-08-09 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use as inhibitors of erk |
| AU2003257094A1 (en) * | 2002-08-08 | 2004-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| KR20120112548A (ko) * | 2009-12-16 | 2012-10-11 | 뉴로포레 테라피스, 인코포레이티드 | 시누클레인 병을 치료하는데 적합한 화합물 |
| US9198891B2 (en) * | 2010-05-21 | 2015-12-01 | New York University | Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase |
-
2013
- 2013-07-16 CN CN201380038158.1A patent/CN104703604A/zh active Pending
- 2013-07-16 HK HK15111382.6A patent/HK1210598A1/xx unknown
- 2013-07-16 MX MX2015000618A patent/MX2015000618A/es unknown
- 2013-07-16 WO PCT/US2013/050719 patent/WO2014014937A1/en not_active Ceased
- 2013-07-16 EP EP13820320.3A patent/EP2872143B1/en active Active
- 2013-07-16 US US14/415,120 patent/US9284309B2/en active Active
- 2013-07-16 BR BR112015001096A patent/BR112015001096A2/pt not_active Application Discontinuation
- 2013-07-16 KR KR20157004215A patent/KR20150031481A/ko not_active Withdrawn
- 2013-07-16 RU RU2015104962A patent/RU2015104962A/ru not_active Application Discontinuation
- 2013-07-16 CA CA2877983A patent/CA2877983A1/en not_active Abandoned
- 2013-07-16 ES ES13820320.3T patent/ES2661394T3/es active Active
- 2013-07-16 AU AU2013290361A patent/AU2013290361A1/en not_active Abandoned
- 2013-07-16 JP JP2015523185A patent/JP2015522617A/ja active Pending
-
2015
- 2015-01-14 IL IL236712A patent/IL236712A0/en unknown
- 2015-02-12 IN IN1171DEN2015 patent/IN2015DN01171A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150183776A1 (en) | 2015-07-02 |
| CN104703604A (zh) | 2015-06-10 |
| ES2661394T3 (es) | 2018-03-28 |
| EP2872143B1 (en) | 2017-12-13 |
| MX2015000618A (es) | 2015-04-10 |
| CA2877983A1 (en) | 2014-01-23 |
| US9284309B2 (en) | 2016-03-15 |
| EP2872143A1 (en) | 2015-05-20 |
| AU2013290361A1 (en) | 2015-02-05 |
| RU2015104962A (ru) | 2016-09-10 |
| IN2015DN01171A (https=) | 2015-06-26 |
| JP2015522617A (ja) | 2015-08-06 |
| EP2872143A4 (en) | 2015-12-02 |
| IL236712A0 (en) | 2015-02-26 |
| WO2014014937A1 (en) | 2014-01-23 |
| KR20150031481A (ko) | 2015-03-24 |
| HK1210598A1 (en) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015001096A2 (pt) | derivados de di e tri-heteroaril como inibidores de agregação de proteína | |
| BR112016018555A8 (pt) | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
| MX383164B (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| BR112014019704A8 (pt) | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo | |
| UA118209C2 (uk) | Гетероариламіди як інгібітори агрегації білків | |
| BR112016024571A2 (pt) | composto de 1,2,4-triazina dissubstituído | |
| BR112015022041A2 (pt) | derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas | |
| BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| TR201908265T4 (tr) | Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. | |
| CO2019002889A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
| BR112019006887A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
| MX2017013571A (es) | Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap). | |
| ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| BR112015028516A2 (pt) | tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |